Gilenya Outperforms Avonex in Lessening Brain Lesion Activity, Atrophy in Children with MS, Trial Shows
News
Oral treatment with Gilenya (fingolimod) is more effective than Avonex (interferon beta-1a) for controlling brain lesion activity and brain volume loss in children with pediatric-onset multiple sclerosis (POMS), two-year results of ... Read more